Tumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance
Recently, immunotherapy has garnered increasing importance in cancer therapy, leading to substantial improvements in patient care and survival. By blocking the immune checkpoints—protein regulators of the immune system—immunotherapy prevents immune tolerance toward tumors and reactivates the immune...
Main Authors: | Valentin Vautrot, Hafidha Bentayeb, Sébastien Causse, Carmen Garrido, Jessica Gobbo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/18/4537 |
Similar Items
-
The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer
by: Yanyan Tang, et al.
Published: (2020-04-01) -
The role of exosomal PD-L1 in tumor immunotherapy
by: Jing Wang, et al.
Published: (2021-05-01) -
Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients
by: Chuling Li, et al.
Published: (2019-10-01) -
Exosomal PD-L1 functions as an immunosuppressant to promote wound healing
by: Dandan Su, et al.
Published: (2020-01-01) -
Engineered Tumor-Derived Extracellular Vesicles: Potentials in Cancer Immunotherapy
by: Adeleh Taghikhani, et al.
Published: (2020-03-01)